Drugs / GLS-5130
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05085639 | Nov 2021 → Apr 2022 | COVID-19 | GeneOne Life Science, Inc. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLS-5130 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05085639 ↗ |